Characteristics of Patients Receiving Pharmaceutical Samples and Association Between Sample Receipt and Out-of-Pocket Prescription Costs

  title={Characteristics of Patients Receiving Pharmaceutical Samples and Association Between Sample Receipt and Out-of-Pocket Prescription Costs},
  author={G. Caleb Alexander and James X Zhang and Anirban Basu},
  journal={Medical Care},
Background:Pharmaceutical samples are widely used for promotion and marketing, yet little is known about who receives samples or how their use is associated with patient's prescription costs. Objective:To examine the characteristics of those receiving samples and the relationship between sample receipt and out-of-pocket prescription costs. Design, Subjects, and Measures:We divided the 2002–2003 Medical Expenditure Panel Survey, a nationally representative, panel-design longitudinal study, into… 

Use of Prescription Drug Samples and Patient Assistance Programs, and the Role of Doctor–Patient Communication

Doctor–patient communication is strongly associated with use of industry-sponsored patient assistance programs, which has important implications for clinical care regardless of whether these programs are viewed as drivers of prescription costs or a remedy for them.

National estimates and predictors of prescription medication sample use in the United States, 1999-2005.

Use of medication samples is common in the U.S. population and after adjusting for health insurance, sample use was not associated with income and samples were less frequently provided to racial/ethnic minorities and to the elderly.

Cost savings associated with filling a 3-month supply of prescription medicines

The findings quantify the cost savings that patients in the US can achieve through filling larger quantities of a prescription for a chronic condition through the use of a 3-month rather than a 1-month supply.

The Impact of Drug Samples on Prescribing to the Uninsured

Physicians were three times more likely to prescribe generic medications to uninsured patients after drug samples were removed from the office, which may paradoxically lead to higher costs if physicians with access to samples prescribe more brand-name only drugs.

Effect of Drug Sample Removal on Prescribing in a Family Practice Clinic

Restriction of pharmaceutical industry representatives and samples from a rural family practice clinic produced modest reductions in branded drug use that varied by class, although aggregate average costs increased, prescriptions for branded and promoted lipid-lowering agents and antidepressants were reduced.

Are patients more adherent to newer drugs?

Patients who use newer drugs are more adherent to pharmacotherapy than patients using older drugs within the same therapeutic class, accounting for unobserved heterogeneity at the individual level (e.g. healthy adherer bias).

Evidence of Sample Use Among New Users of Statins: Implications for Pharmacoepidemiology

These results provide indirect evidence that the initial period of branded medication use may often be missed when using pharmacy claims data to define drug initiation, and approach to better identify incident medication use when assessing short-term effects.

Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology

Drug-specific sample provision rates based on nationally projected data from a survey of over 3200 US office-based physicians for 1993–2013 found pronounced drops in sample provisions over time coinciding with more recent generic approval dates.

The impact of manufacturer coupon use in the statin market.

Brand-name statin initiators using coupons have higher adherence than patients initiating generic statins or brand- name statins without coupons, and higher adherence among coupon users appears to occur at the expense of higher out-of-pocket and total statin expenditures.

Association Between the Commercial Characteristics of Psychotropic Drugs and Their Off-label Use

The findings suggest that drug prescription volume, rather than product age or therapeutic class age, should be scrutinized further to identify settings where the public health impact of unsupported off-label prescribing may be particularly important.



Effect of antihypertensive samples on physician prescribing patterns.

The prescription of first-line drugs for the treatment of hypertension increased after drug sample distribution was prohibited and studies are needed to determine the extent to which drug sample availability affects prescription practices.

The value of pharmaceutical representative visits and medication samples in community-based family practices.

Clinicians have a complex symbiosis with the pharmaceutical industry and need to critically evaluate their handling of samples and their contact with pharmaceutical representatives to optimize this relationship and ensure quality patient care.

Physician strategies to reduce patients' out-of-pocket prescription costs.

The findings suggest that patient-physician communication about out-of-pocket costs is a problem affecting specialists and generalists nationwide and despite barriers, physicians use multiple strategies that may vary in efficacy to assist patients burdened by these costs.

Prescription drug use and self-prescription among resident physicians.

Although self-prescription is difficult to evaluate, the source of these medications and the lack of oversight of medication use raise questions about the practice.

Prescription drug samples – does this marketing strategy counteract policies for quality use of medicines?

This manuscript critically evaluates the research that has been conducted to date about prescription drug samples, discusses the issues raised in the context of traditional marketing theory, and suggests possible alternatives for the future.

Scale of interest versus scale of estimation: comparing alternative estimators for the incremental costs of a comorbidity.

This work uses a variety of goodness-of-fit measures along with a modified Copas test to assess robustness, lack of fit, and over-fitting properties of the alternative estimators and finds a new flexible model to appropriately represent the scale of estimation and less susceptible to over- fitting despite estimating additional parameters in the link and the variance functions.

Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior

The authors find that physicians are characterized by fairly limited price sensitivity, detailing and samples have a mostly informative effect on physicians, and physicians with a relatively large number of Medicare or health maintenance organization patients are less influenced by promotion than other physicians are.

Estimating marginal and incremental effects on health outcomes using flexible link and variance function models.

The proposed estimation method not only helps to identify an appropriate link function and to suggest an underlying distribution for a specific application but also serves as a robust estimator when no specific distribution for the outcome measure can be identified.

The Effects of Free Sample Promotions on Incremental Brand Sales

The authors present a model of free sample effects and evidence from two field experiments on free samples. The model incorporates three potential effects of free samples on sales: (1) an

Problems with Instrumental Variables Estimation when the Correlation between the Instruments and the Endogenous Explanatory Variable is Weak

Abstract We draw attention to two problems associated with the use of instrumental variables (IV), the importance of which for empirical work has not been fully appreciated. First, the use of